- Home
- BMO vs VRTX Comparison
BMO vs VRTX Comparison
Compare BMO & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMO | VRTX |
|---|---|---|
| Founded | 1817 | 1989 |
| Country | Canada | United States |
| Employees | 53000 | N/A |
| Industry | Commercial Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.6B | 115.7B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | BMO | VRTX |
|---|---|---|
| Price | $175.24 | $491.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 29 |
| Target Price | $163.00 | ★ $539.69 |
| AVG Volume (30 Days) | 610.2K | ★ 1.3M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 4.02 |
| Revenue | N/A | ★ $2,488,652,000.00 |
| Revenue This Year | $19.43 | $10.79 |
| Revenue Next Year | $4.27 | $10.47 |
| P/E Ratio | ★ $17.46 | $119.31 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $109.31 | $362.50 |
| 52 Week High | $175.21 | $509.98 |
Technical Indicators
Market Signals| Indicator | BMO | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 74.96 | 72.21 |
| Support Level | $122.60 | $420.66 |
| Resistance Level | N/A | $506.93 |
| Average True Range (ATR) | 2.65 | 12.22 |
| MACD | 0.24 | 4.26 |
| Stochastic Oscillator | 92.92 | 77.76 |
Price Performance
Historical ComparisonAbout BMO Bank Of Montreal
Bank of Montreal is a diversified financial services provider based in North America with over CAD 1.47 trillion in assets by the end of fiscal 2025. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. About 60% of BMO's earnings are generated in Canada and 40% in the US.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.